Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Indofarma Tbk. (INAF) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance

Indofarma Tbk.Trade
Organon Pharma Indonesia Tbk.Trade

Price performance (Past 24H)

Key statistics

Indofarma Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Indofarma Tbk. trades at Rp126 (market cap 390.51B), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Indofarma Tbk. is far larger — about 3.7× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.

INAFSCPI
Market Cap
390.51B104.4B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INAF
View details
SCPI
View details

About Indofarma Tbk.

PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.

Read more on INAF

About Organon Pharma Indonesia Tbk.

PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.

Read more on SCPI